1-(4-Tert-butylcyclohexyl)-4-methylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-Tert-butylcyclohexyl)-4-methylpiperazine
• 化学式: C₁₅H₃₀N₂
• 分子量: 238.41
• InChiKey: HUVFJMFBYAIHPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Use of pteridinone derivative serving as EGFR inhibitor
  申请人：EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

  公开号：US11306095B2

  公开（公告）日：2022-04-19

  The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.

  本发明涉及一种作为表皮生长因子受体抑制剂的蝶啶酮衍生物及其用途。具体地说，本发明涉及由下式I代表的化合物、包含下式I化合物的药物组合物，以及该化合物在制备治疗表皮生长因子受体介导的疾病或抑制表皮生长因子受体的药物中的用途。
• PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE
  申请人：BETTA PHARMACEUTICALS CO., LTD

  公开号：US20160145237A1

  公开（公告）日：2016-05-26

  Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.
• USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR
  申请人：EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

  公开号：US20180148454A1

  公开（公告）日：2018-05-31

  The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.
• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION
  申请人：G1 Therapeutics, Inc.

  公开号：US20200331925A1

  公开（公告）日：2020-10-22

  This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
• US9783524B2
  申请人：——

  公开号：US9783524B2

  公开（公告）日：2017-10-10